A vs RVTY
A: A diversified healthcare and life sciences company providing analytical instruments, software, and services for pharmaceutical, chemical, and clinical diagnostics laboratories worldwide. RVTY: Revvity provides a comprehensive suite of life science and diagnostic technologies, powering workflows from research discovery to clinical breakthroughs.
Side-by-side fundamentals
| Metric | A | RVTY | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $141.34 | $114.24 | |
| Market cap as of 2026-08-08 | $39.9B | $12.7B | |
| P/E as of 2026-08-08 | 28.69 | 53.75 | A lower |
| PEG as of 2026-08-08 | 3.55 | 5.81 | A lower |
| Net margin as of 2026-08-08 | +19.6% | +8.2% | A higher |
| Gross margin as of 2026-08-08 | +52.9% | +55.0% | RVTY higher |
| Operating margin as of 2026-08-08 | +21.5% | +12.3% | A higher |
| ROE as of 2026-08-08 | +20.8% | +3.3% | A higher |
| ROA as of 2026-08-08 | +11.1% | +2.0% | A higher |
| Debt / equity as of 2026-08-08 | 0.47 | 0.44 | RVTY lower |
| Revenue growth (YoY) as of 2026-08-08 | +9.1% | +4.0% | A higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | -9.3% | A higher |
| Dividend yield as of 2026-08-08 | +0.7% | +0.2% | A higher |
| Dividend streak (yrs) SEC XBRL | 5 | 3 | A higher |
| Beta as of 2026-08-08 | 1.23 | 1.07 | |
| 1-year return as of 2026-08-06 close | +24.8% | +33.0% | RVTY higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.